Bettina Hansen
0000-0001-8307-3341
Leiden University Medical Centre
404 papers found
Refreshing results…
Hbsag Decline During Peginterferon Alfa-2b Therapy for Hbeag-Positive Chronic Hepatitis B Depends on HBV Genotype: Relation to Sustained Response
Liver-Derived Micrornas in Serum Are Sensitive Biomarkers for Hepatic Injury in Chronic Hepatitis C
Prediction of Sustained Response to Peginterferon Alfa-2b for Hbeag-Positive Chronic Hepatitis B Using on-Treatment Hbsag Decline
Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice
Sperm Dna Integrity Is Not Affected by Treatment With Peginterferon Alfa and Ribavirin for Chronic Hepatitis C
Hbsag Levels During Antiviral Therapy for Chronic Hepatitis B: Peginterferon Versus Entecavir
Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid.
Effect of Anticoagulation Therapy in Patients With Non Cirrhotic Extrahepatic Portal Vein Thrombosis
Ascites in Patients With Non- Cirrhotic Non- Malignant Extrahepatic Portal Vein Thrombosis
Peginterferon Alfa-2b Induced Hbsag Decline Is Durable Through Long-Term Follow-Up in Hbeag-Positive Patients
Tobacco Consumption Is No Independent Risk Factor of Hepatic Steatosis: Results of a Population-Based Study
Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon–ribavirin combination therapy after 4 weeks of treatment
Early on-Treatment Hbsag and HBV Dna Levels Identify Hbeag-Negative Patients Not Responding to 48 or 96 Weeks of Peginterferon Alfa-2a Therapy
Dynamic Update of 5-and 10-Year Risk of Liver Failure of Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cirrhosis Including Bilirubin and Albumin Observed During Follow-Up
Continuous Subcutaneous Administration of High-Dose Interferon Alfa-2b Combined With Ribavirin in Chronic Hepatitis C Patients: A Dose-Finding and Safety Study in Treatment-Experienced Patients
Treatment Adaptation Is Not Needed for the Majority of Partial Virological Responders to Entecavir: Results From 326 Chronic Hepatitis B Patients in an International Multicenter Cohort Study
Viral Kinetics and Immunological Response With Continuous Subcutaneous Administration of High-Dose Interferon Alfa-2b in Treatment-Experienced Chronic Hepatitis C Patients
Serum Hbsag Levels Decrease Through Long-Term Follow-Up in Hbeag-Negative Patients Achieving a Sustained Response to Peginterferon Alfa-2a
Prediction of Hbsag Loss Using Hbsag Decline After Long-Term Virological Response to Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
Stronger HBV Dna Suppression in Patients With Hbeag-Positive Chronic Hepatitis B Achieving Hbeag Clearance During Peginterferon Alfa-2b Therapy Compared With Placebo
Missing publications? Search for publications with a matching author name.